Previous close | 1.9300 |
Open | 2.5700 |
Bid | 0.0000 |
Ask | 4.9000 |
Strike | 155.00 |
Expiry date | 2024-10-18 |
Day's range | 1.9300 - 2.5700 |
Contract range | N/A |
Volume | |
Open interest | 13 |
Biogen stock jumped Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?